Literature DB >> 14505158

Constipation--modern laxative therapy.

E Klaschik1, F Nauck, C Ostgathe.   

Abstract

It is estimated that one third of the population in Western industrial countries suffers from constipation at least from time to time. Constipation may have somatopathic or functional causes. Furthermore, a great number of substances are known to cause medication-induced constipation, i.e. opioid-induced constipation is caused by linkage of the opioid to opioid receptors in the bowel and the central nerve system. Whenever possible, causal therapy should be undertaken. Patients in palliative care mostly suffer from chronic functional constipation. The treatment consists of basic measures and the application of laxatives. According to their mode of action, they are divided into bulk-forming laxatives, osmotic laxatives, stimulant laxatives, lubricating agents and others. Bulk-forming laxatives are not recommended for use in palliative care patients, for such patients are normally not able to take in the required amount of fluids. Osmotic laxatives are divided into (magnesium) salts, saccharine, alcohols and macrogols. Lactulose is the most popular saccharine laxative. Because of its side effects (flatulence, bloating and abdominal cramping), lactulose is not a laxative of our choice; instead, we prefer to give macrogol. Orally administered, macrogol is not metabolised and pH value and bowel flora remain unchanged. Macrogol hydrates hardened stools, increases stool volume, decreases the duration of colon passage and dilates the bowel wall that then triggers the defecation reflex. Even when given for some time, the effectiveness of macrogol will not decrease. Because of its high effectiveness and commonly good tolerance, macrogol has become the laxative of first choice in palliative care patients with all kinds of chronic constipation, if these patients are able to take in the necessary amount of fluids. From the general medical point of view, lubricating agents have become obsolete. In palliative care patients, however, they are still important laxatives for prophylactic treatment or therapy of constipation. Due to clinical experience, in palliative care a laxative ladder has proven successful.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14505158     DOI: 10.1007/s00520-003-0525-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  15 in total

1.  A new weapon for the arsenal in the war against constipation?

Authors:  H M Lasch; E M Bozymski
Journal:  Am J Gastroenterol       Date:  2000-02       Impact factor: 10.864

2.  Epidemiology of constipation in the United States.

Authors:  A Sonnenberg; T R Koch
Journal:  Dis Colon Rectum       Date:  1989-01       Impact factor: 4.585

3.  Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters.

Authors:  K W Heaton; L J O'Donnell; F E Braddon; R A Mountford; A O Hughes; P J Cripps
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

4.  [Principles of chronic pain therapy with opioids. Results of a Sertürner workshop "Chronic Opioid Therapy"].

Authors:  A Willweber-Strumpf; M Zenz; M Tryba
Journal:  Anaesthesist       Date:  1995-10       Impact factor: 1.041

5.  [Treament of morphine-induced constipation with oral naloxone].

Authors:  L Latasch; M Zimmermann; B Eberhardt; I Jurna
Journal:  Anaesthesist       Date:  1997-03       Impact factor: 1.041

6.  Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features.

Authors:  W F Stewart; J N Liberman; R S Sandler; M S Woods; A Stemhagen; E Chee; R B Lipton; C E Farup
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

7.  Functional constipation and outlet delay: a population-based study.

Authors:  N J Talley; A L Weaver; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1993-09       Impact factor: 22.682

8.  Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation.

Authors:  E Corazziari; D Badiali; G Bazzocchi; G Bassotti; P Roselli; G Mastropaolo; M G Lucà; R Galeazzi; E Peruzzi
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

Review 9.  The epidemiology of functional gastrointestinal disorders in North America.

Authors:  G R Locke
Journal:  Gastroenterol Clin North Am       Date:  1996-03       Impact factor: 3.806

10.  Polyethylene glycol 4000 for slow transit constipation.

Authors:  A G Klauser; B E Mühldorfer; W A Voderholzer; G Wenzel; S A Müller-Lissner
Journal:  Z Gastroenterol       Date:  1995-01       Impact factor: 2.000

View more
  25 in total

1.  [Strong opioids and constipation].

Authors:  A Schwarzer; F Nauck; E Klaschik
Journal:  Schmerz       Date:  2005-06       Impact factor: 1.107

2.  Dorsal acoustic windows may ameliorate liver ultrasound in patients with chronic liver disease and meteorism/obesity/ascites.

Authors:  Marco Domenicali; Manuel Tufoni; Vittoria Bevilacqua; Barbara Benazzi; Carmen Serena Ricci; Alessandra Tovoli; Lucia Napoli; Paolo Caraceni; Mauro Bernardi
Journal:  J Med Ultrason (2001)       Date:  2013-05-11       Impact factor: 1.314

Review 3.  Current and emerging pharmacotherapeutic options for irritable bowel syndrome.

Authors:  Jose L Barboza; Nicholas J Talley; Baharak Moshiree
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 4.  Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives.

Authors:  L Stavitskaya; A Coop
Journal:  Mini Rev Med Chem       Date:  2011-10       Impact factor: 3.862

Review 5.  New treatments for irritable bowel syndrome in women.

Authors:  Mopelola A Adeyemo; Lin Chang
Journal:  Womens Health (Lond)       Date:  2008-11

6.  Medical treatment of constipation.

Authors:  Jonathan D Siegel; Jack A Di Palma
Journal:  Clin Colon Rectal Surg       Date:  2005-05

Review 7.  [Opioid-induced bowel dysfunction: a literature analysis on pathophysiology and treatment].

Authors:  Jürgen Osterbrink; Ute Haas
Journal:  Wien Med Wochenschr       Date:  2008

8.  Medical management of constipation.

Authors:  Meredith Portalatin; Nathaniel Winstead
Journal:  Clin Colon Rectal Surg       Date:  2012-03

Review 9.  [Methylnaltrexone. A new approach for therapy of opioid-induced obstipation].

Authors:  D Chappell; P Conzen
Journal:  Schmerz       Date:  2009-10       Impact factor: 1.107

10.  Pharmaceutical interventions facilitate premedication and prevent opioid-induced constipation and emesis in cancer patients.

Authors:  Masashi Ishihara; Hirotoshi Iihara; Shinji Okayasu; Koji Yasuda; Katsuhiko Matsuura; Masumi Suzui; Yoshinori Itoh
Journal:  Support Care Cancer       Date:  2009-11-18       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.